Navigation Links
Adding blood pressure drug to standard antibiotics speeds up TB treatment
Date:8/29/2013

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

Researchers say that if clinical trials starting later this year in India, a country heavily burdened by the highly contagious lung disease, prove successful, then the shortened treatment time with verapamil, a so-called calcium channel blocker, used in combination with antibiotics isoniazid and rifampin, could make it easier for infected people to complete their drug therapy as prescribed. The experts note that antibiotics for TB do not work if treatment is interrupted or if people stop taking their medication. Improved drug adherence, they say, could also prevent the buildup of drug-resistant strains of TB, caused by Mycobacterium tuberculosis, which is now estimated to kill a million people each year, mostly in the developing world.

"Our results show that verapamil is a good drug candidate as an add-on therapy with antibiotics for TB, a global disease in urgent need of new treatment options," says study senior investigator and infectious disease specialist William Bishai, M.D., Ph.D. Bishai's team's latest findings are set to be published in the Sept. 1 edition of the American Journal of Respiratory and Critical Care Medicine.

Bishai, a professor at the Johns Hopkins University School of Medicine and its Center for Tuberculosis Research, says that drug treatment options for TB are "too few," and limited to about a dozen older antibiotics, some with serious side effects. Bishai, who also is a Howard Hughes Medical Institute Lab Head at Johns Hopkins, says verapamil has been around for some 40 years, so its side effects -- such as too-low blood pressure -- are well-known. He says the clinical trial in India, primarily a safety study to determine a minimum effective dose, will be pivotal in clarifying the drug's "true potential" as an add-on therapy in TB.

Lead study investigator and immunologist Shashank Gupta, Ph.D., says the study results also suggest that verapamil, commonly sold under the brand names Isoptin, Verelan, Calan, Bosoptin and Covera, could be a good drug candidate for combination therapy studies with multidrug-resistant forms of TB.

Gupta, a postdoctoral fellow at Johns Hopkins, says verapamil is known to work as an efflux pump inhibitor, making bacteria more susceptible to antibiotics and killing by immune cell macrophages, but whose precise workings remain unknown. He says the research team investigated verapamil's potential as a TB therapy after another study showed that increased efflux pump action promoted drug tolerance to TB, minimizing antibiotics' effectiveness.

Among the latest study's other key findings were that verapamil accelerated killing of TB bacteria 10-fold after two months of treatment. After four months of therapy, half of the lung tissue samples from mice receiving verapamil had zero bacterial counts, while all tissue samples in mice not on the blood pressure medication were still positive for TB.

In the study, performed at Johns Hopkins from January to November 2012, mice infected with TB were treated with a standard antibiotic regimen of daily doses of isoniazid, rifampin and pyrazinamide for two months, followed by daily doses of just isoniazid and rifampin for four months. Half of the infected mice also received daily doses of verapamil, equivalent to the minimum dose manufactured for use in humans, at 40 milligrams per liter of blood, for the entire six months. Researchers calculated a 50 percent increase in the original dosage of verapamil used in the study to compensate for rifampin's acceleration of verapamil's breakdown in the body. Both groups of mice had lung tissue analyses performed at least monthly.


'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. 123Greetings Launched Spanish, Chinese, Russian, & Hindi Ecards Under World Languages, Adding Diversity To Its Collection
2. Gentek Building Products, Inc. Class Action Settlement Approved, Reports Parker Waichman LLP, Adding that Partner Jordan L. Chaikin Has Been Appointed Settlement Class Counsel
3. AlignLife of Wauwatosa Growing and Adding More Staff
4. DietNoodleShop.com is Re-launching; Adding More Diet Recipes Along with Information on Shirataki Noodles
5. Medical Tourism Portal Grows its List of Destinations by Adding South Korea
6. New Century Coal Signs Option Adding Over 5 Million Tons; Set to Become Industry Reserve Leaders
7. Adding Patient Photos to X-Rays May Cut Identification Errors
8. Muscular Development Store Comments on Article Suggesting Adding Coffee to Your Pre-Workout Routine
9. Popular Medical Tourism Portal, myMEDholiday.com, Expands Its Functionality by Adding RSS Feeds
10. Fewer people adding salt at the table
11. Adding bavituximab to second-line chemotherapy doubles response rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology: